Pharmaceuticals & Therapeutics

A new $3M grant program targets the immune system's role in neurodegeneration, funding bold new research to combat Alzheimer's and Parkinson's.

The new pre-configured kits aim to reduce patient confusion and improve outcomes, tapping into the growing multi-billion dollar home healthcare market.

As Stryker preps its Q1 2026 report, all eyes are on whether the MedTech giant can sustain its momentum amid new products and industry-wide pressures.

In a tough biotech market, NewcelX's $1.35M financing at a 30% premium signals strong confidence in its pioneering stem cell therapy for Type 1 Diabetes.

A 30-second 'Healthy Selfie' now detects metabolic risk. Backed by a $200K guarantee, this AI platform is set to redefine corporate wellness.

As China surpasses the US in key research metrics, a new English platform aims to bridge the information gap for global scientists and innovators.

China’s top infant formula maker is rewriting the global playbook, using cutting-edge research and local insight to challenge established giants in Southeast Asia.

The Our Health Our Wellness campaign aims to close critical health disparity gaps with resources, events, and education for underserved communities.

Glenmark Pharmaceuticals challenges established brands with its new GLN-Minoxidil 5% foam, aiming to make hair regrowth treatment more accessible and convenient.

NewBeauty's 16th annual awards spotlight 395 winners, signaling a major shift towards science-backed efficacy and holistic health in the beauty market.

Longhorn Diagnostics unveils LHNVD-501, a novel antibody targeting a universal bacterial component, offering a new front against AMR and chronic inflammation.

Biotech startup Infinimmune's 'human-first' AI platform lands a major deal with Merck, aiming to revolutionize how new antibody drugs are created.

The pharma giant expands its collaboration with OpenProtein.AI, integrating advanced AI to accelerate the creation of new drugs for cancer and autoimmune diseases.

A new Phase 2 trial for an oral pill offers hope for patients with M. abscessus lung disease, a severe infection with no approved treatments.

The neurotech pioneer reports strong sales for its spinal cord injury therapy, secures key FDA approvals, and plans for major US stock market entry.

With improved financials and progress on therapies for cannabis use disorder and Down syndrome, the French biotech charts a confident course for the future.

A new drug not only reduces osteoarthritis pain significantly but may also be the first to modify the disease itself, a landmark study in The Lancet reveals.

LIB Therapeutics' new monthly, room-temperature stable cholesterol drug shows strong long-term data, challenging rivals with a focus on patient ease-of-use.

After promising results in a key patient subgroup, the PREVAiLS study will test if pridopidine can slow the relentless progression of ALS.

Amid a tough biotech market, the firm extends its cash runway to 2027, accelerating development of its promising rademikibart treatment for respiratory diseases.